Autism Spectrum Disorder (ASD) is a lifelong condition marked by challenges in social communication and repetitive behaviors. Current treatments, primarily behavioral therapies, often fail to address the core symptoms. Recent research has explored the potential of psychedelics, such as LSD, psilocybin, and MDMA, as a new therapeutic approach. While these substances primarily modulate the...
Abstract Current psychiatric assessment relies on symptom checklists, self-report, and single-timepoint neuroimaging—none of which answer the critical question: has a therapeutic intervention produced sustainable structural change, or merely temporary perturbation? This paper presents a theoretical framework derived from Coherence-Decoherence-Recovery (CDR) basin dynamics, regulatory capacity...
Prolonged obesity induces enduring structural changes within neural circuits that contribute to maintaining the body at an elevated/obese body weight. These circuits regulate various mechanisms which can inhibit extreme or persistent weight loss. Therefore, a potential therapeutic strategy to facilitate weight loss is to promote structural plasticity within the brain. Psychedelic compounds,...
The clinical importance of iboga alkaloids lies in their efficacy in reversing drug addiction and modulating drug tolerance. However, due to safety concerns, their use is restricted to appropriate medical supervision. These alkaloids often cause severe psychedelic effects due to differential binding to various brain receptors and cardiotoxicity by blocking the human ether-a-go-go-related gene...
Introduction: Psilocybin therapy has demonstrated efficacy for cancer-related anxiety and depression, but resource-intensive individual treatment models raise important questions for psychedelic public health about equitable access and scalability. In our prior Phase 1/2 study of group retreat psilocybin therapy for patients with metastatic cancer, we observed partial responders who did not...
Excitement has built recently about new avenues for psychiatric treatment: psychedelic drugs such as Ketamine and psilocybin; trans‐cranial magnetic stimulation (TMS). We see the revival of older practices such as electro‐convulsive shock therapy (ECT) and therapeutic lesioning, and medicines borrowed from other fields, like GLP‐1s.
PsychoactivesApril 13, 2026J. Morgan Penberthy, Fatma Wise, Nicholas P. Cherup et al.
Prolonged grief disorder (PGD) affects approximately 10% of bereaved individuals and is now formally recognized in both the DSM-5-TR and ICD-11. Despite its prevalence, PGD often responds poorly to traditional therapeutic approaches. This manuscript outlines the protocol for an early-stage open-label feasibility trial investigating the use of psilocybin, a psychedelic compound, in treating PGD...
For the past half-century, psychiatric drug development has largely focused on tweaking neurotransmitter receptors and chemical pathways. Yet despite billions of dollars invested and major advances in neuroscience, truly innovative treatments for mental illness remain scarce. Disorders like depression, schizophrenia, and post-traumatic stress disorder (PTSD) continue to be managed with drugs...
Este artículo presenta una revisión narrativa sobre las variables extrafarmacológicas que influyen en la terapia asistida con psicodélicos (TAPs). A partir del análisis de literatura reciente, se destaca la importancia de la persona (set) y el ambiente (setting) en la modulación de los efectos subjetivos y terapéuticos de sustancias como la psilocibina o el MDMA. El objetivo principal fue...
Non-Ordinary Experiences (NOEs), encompassing phenomena such as feelings of cosmic or divine unity and sensing the presence of deceased persons, are common in the general population of different countries. Despite a recent increase in the number of studies investigating the implications of these experiences for mental health and well-being, no review comprehensively synthesizing existing...